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Objectives. This study assessed the effect of the combination of 
aspirin and dipyridamole on patency of the infarct-related artery 
between 4 weeks and 1 year after myocardial infarction. 
Background. Patency of the infarct-related artery is an impor- 
tant determinant of prognosis after myocardial infarction. The 
incidence of late reocclusion and the effects of antiplatelet herapy 
are unknown. 
Methods. To investigate the importance of antiplatelet herapy 
for the prevention of late reocclusion, 215 patients who had a 
patent infarct-related artery 4 weeks after myocardial infarction 
were randomized in a double-blind manner to receive either a 
combination of 25 mg of aspirin and 200 mg of dipyridamole twice 
daily or placebo. One hundred fifty-four patients underwent 
further coronary arteriography 1 year later. 
Results. At 1 year, 38 (25%) of 154 patients had reocclusion of 
the infarct-related artery; 18 (23%) of 79 patients receiving 
aspirin and dipyridamole had late reocclusion versus 20 (27%) of 
75 who received placebo (p = NS). The rate of reocclusion was 
related to the severity of the residual coronary artery stenosis at 
4 weeks (<50% stenosis 9.2%; 50% to 69% stenosis 11.6%; 70% to 
89% stenosis 30.4%; >90% stenosis 70%, p < 0.01). The majority 
of reocclusions were silent, and only 17 (45%) of 38 were clinically 
associated with further infarction. There were no differences for a 
hierarchic end point of cardiac death, myocardial infarction or 
revascularization (14.8% aspirin and dipyridamole vs. 17.8% 
placebo). 
Conclusions. Late reoeclusion of the patent infarct-related 
artery is a frequent event, occurring in 25% of patients. Antiplate- 
let therapy with the combination of aspirin and dipyridamole does 
not alter the overall rate of late reocclusion. Other strategies are 
required to reduce late reocclusion. 
(JAm Coil Cardio11995;25:218-23) 
There are a number of factors associated with a poor long-term 
prognosis after acute myocardial infarction, including left 
ventricular function, in particular dilation (1), extent of coro- 
nary artery disease (2), inducible myocardial ischemia (3), 
ventricular arrhythmias (4), decreased heart rate variability 
(5), continued cigarette smoking (6) and dyslipoproteinemia 
(7). More recently, an occluded infarct-related artery was 
shown (8) to be an independent adverse long-term prognostic 
factor. 
Patency of the infarct-related artery is a dynamic process 
that may change in the initial hours, days and weeks after acute 
myocardial infarction (9-11). Changes in patency occur in 
patients with and without hrombolytic therapy. The incidence 
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of late reocclusion of the infarct-related artery is unknown. 
The mechanisms that determine longer term patency are 
unclear but may include the degree of residual stenosis, flow 
characteristics, tiffness and size of the infarction, extent of 
microvascular injury and abnormalities of lipid metabolism, 
coagulation and blood rheology. 
In an attempt o address the role of antiplatelet therapy 
in maintaining patency of the infarct-related artery, we 
studied patients with a patent infarct-related artery 4 weeks 
after myocardial infarction (Thrombolysis in Myocardial 
Infarction trial [TIMI] flow grade 3 or 2 [12]) who were 
randomized to receive either a combination of aspirin and 
dipyridamole or a matching placebo in a double-blind 
manner. At 1 year, coronary arteriography was repeated. 
These patients had previously been randomized to receive 
placebo, streptokinase or recombinant tissue-type plasmin- 
ogen activator (rt-PA) as part of two trials of thrombolytic 
therapy (13,14). A conservative approach to intervention 
was adopted (15), and over the year only 5% of patients 
underwent coronary artery bypass grafting or coronary 
angioplasty. 
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Methods  
Study patients. The study group included 215 consecutive 
patients who received intravenous thrombolytic therapy (176 
patients) or placebo (39 patients) ---6 h after the onset of 
->30 rain of ischemic hest pain with ST segment elevation on 
the electrocardiogram (ECG) and who did not have contrain- 
dications for thrombolytic therapy (13,14). Written informed 
consent was obtained from each patient, and the trial was 
approved by the ethics committees of the four participating 
hospitals in Auckland. 
Thrombolytic and adjunctive therapy. Intravenous strep- 
tokinase (1.5 × 10 6 IU) was administered over 30 rain to 107 
patients. Sixty-nine patients received 100 mg of rt-PA admin- 
istered as a 10-mg bolus followed by 50 mg infused over 1 h and 
40 mg over the next 2 h. Thirty-nine patients were randomized 
to receive placebo and did not receive thrombolytic therapy. 
Heparin was administered byintravenous infusion for 24 h at 
an initial dose of 1,000 IU/h immediately after completion of 
thrombolytic therapy, with subsequent dose adjustment to 
maintain an activated partial thromboplastin time of 90 to 
110 s. Oral beta-adrenergic blocking agent herapy was initi- 
ated in patients without contraindications -<3 days after hos- 
pital admission. 
A combination of 25 mg of aspirin and 200 mg of dipyrid- 
amole (Asasantin, Boehringer Ingelheim) was given orally 
before the blinded thrombolytic infusion and continued twice 
daily. At the time of cardiac catheterization 4 weeks after 
myocardial infarction, patients with a patent infarct-related 
artery were randomized in a double-blind manner to either 
continue receiving aspirin and dipyridamole or to receive 
placebo. Patients also underwent symptom-limited treadmill 
exercise testing by the modified Bruce protocol. 
Patients were reviewed every 3 to 6 months. Severe angina 
(grade III or IV) (16) refractory to medical therapy was treated 
with angioplasty or coronary artery bypass grafting. Medical 
therapy in such cases generally included beta-blockade, a 
calcium antagonist and nitrates. Intervention was not per- 
formed solely on the basis of anatomic findings, with the 
exception of operation for left main coronary stenosis. Recur- 
rent myocardial infarction was defined as chest pain accompa- 
nied by elevation in serum creatine kinase (CK) levels above 
the upper limit of the reference range for our laboratory (300 
IU/liter) with or without ypical ECG changes. 
Angiographic analysis. Coronary arteriography and left 
ventriculography were undertaken ata median time of 27 days 
and 13.5 months after initial infarction in consenting patients. 
Sublingual nitroglycerin was given before coronary arteriogra- 
play. Patency of the infarct-related artery was classified accord- 
ing to the TIMI criteria (12). Arteries with TIMI grade 0 (no 
perfusion) and TIMI grade 1 flow (penetration without perfu- 
sion) were classified as occluded, and TIMI grade 2 (partial 
peffusion with slow filling) and TIMI grade 3 flow (complete 
perfusion) as patent. The infarct-related artery was determined 
from the admission ECG, wall motion abnormality on the 
ventriculogram and possible presence of thrombus in the 
Table 1. Baseline Characteristics of the 215 Study Patients 
Aspirin and Placebo 
Dipyridamole Group Group p 
(n - 107) (n = 108) Value 
Age (yr) 55 +_ 9 56 _+ 9 0.46 
Male gender 86 (80%) 86 (80%) 1.00 
Yhrombolytic agent 
Streptokinase 51 (48%) 56 (52%) 
rt-PA 37 (35%) 32 (30%) 0.73* 
Placebo 19 (18%) 20 (19%) 
Smokert 63 (59%) 71 (66%) 0.37 
Diabetes mellitus 11 (10%) 7 (6%) 0.45 
Hypertension 27 (25%) 28 (26%) 1.00 
Beta-blocker therapy 65 (61%) 59 (55%) 0.44 
Total cholesterol (mmol/liter) 6.2 + 1.2 6.3 _+ 1.1 0.62 
HDL cholesterol (mmo[/liter) 0.94 _+ 0.61 0.99 _+ 0.34 0.55 
Triglycerides (mmol/liter) 2.1 _+ 1.3 1.9 _+ 1.1 0.30 
*Three by two chi-square analysis, tSmoking up to time of myocardial 
infarction. Data presented are mean value - SD or number (%) of patients. 
HDL - high density lipoprotein; rt-PA = recombinant tissue-type plasminogen 
activator. 
artery. The culprit stenosis of the infarct-related artery was 
defined as either the most severe proximal stenosis or a 
stenosis identified with thrombus. Coronary artery stenoses 
were assessed in two orthogonal views and measured by 
experienced cardiac radiologists (1,13,15,17). Left ventriculog- 
raphy was performed simultaneously in the right anterior 
oblique and cranially angulated left anterior oblique projec- 
tions. Ventricular volumes and ejection fraction were calcu- 
lated as previously described (1,13,14). 
Statistical analysis. The frequency of angiographic reoc- 
clusion of the infarct-related artery >4 weeks after myocardial 
infarction was unknown, and the size of this study was based on 
the hypothesis that antiplatelet therapy might produce a 
reduction i  reocclusion of the infarct-related artery from 25% 
to 12.5% over 1 year; this would have required 150 patients for 
80% power (p < 0.05). The assumed rate of 25% was based on 
rates of in-hospital reocclusion seen with rt-PA and streptoki- 
nase (18-20). We hypothesized that because aspirin has been 
shown (Second International Study of Infarct Survival [ISIS-2] 
[21]) to reduce reinfarction by 50% in patients after myocar- 
dial infarction, antiplatelet therapy might reduce reocclusion 
(some of which may be silent) by a similar amount. 
Results for continuous variables are expressed as mean 
value + SD, and differences between mean values are com- 
pared by one-way analysis of variance. All p values reported 
are two-tailed. Categoric variables are compared by the chi- 
square test with the Yates correction for continuity in two by 
two tables; p < 0.05 was statistically significant. 
Resul ts  
Patient characteristics and follow-up. Baseline character- 
istics (Table 1) were similar in those patients randomized to 
receive aspirin and dipyridamole or placebo. Of the 215 
patients randomized, 10 had died at 1 year. Of the 205 patients 
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Table 2. Clinical Outcome at 1 Year 
Follow-Up Arteriogram at 1 yr No Follow-Up Arteriogram All Patients 
Aspirin and Dipyridamole Placebo Aspirin and Dipyridamole Placebo Aspirin and Dipyridamole Placebo 
Group Group Group Group Group Group 
(n = 79) (n = 75) (n = 2g) (n = 33) (n = 108) (n = 107) 
Death 0 0 4 (2)* 6 4 (2)* 6 
Nonfatal reinfarction 7 6 2 2 9 8 
PTCA 2 3t 0 0 2 3t 
CABG 3 1 1 2 4 3 
Unstable angina 0 2 
*Parentheses indicate noncardiac deaths, tOne patient subsequently had coronary artery bypass graft surgery (CABG) but is only counted for the first 
revascularization procedure. PTCA = percutaneous transluminal coronary angioplasty. 
available for repeat coronary arteriography, 154 (75%) under- 
went this procedure. Fifty-one patients declined. There were 
no differences in baseline characteristics of patients who were 
and who were not restudied. 
Mortality and cardiac events. During the year after the 
initial arteriogram, 10 patients died (6 in the placebo group 
[3 died suddenly; 1 had ventricular fibrillation]; 4 in the aspirin 
and dipyridamole group [1 died suddenly]) (Table 2). Two 
patients in the group receiving aspirin and dipyridamole died 
of noncardiac auses (one had cancer, one renal failure). Two 
patients in the placebo group died after reinfarction, and one 
patient in the aspirin and dipyridamole group died after 
coronary artery bypass graft surgery. 
Seventeen patients (nine in the placebo group, eight in the 
aspirin and dipyridamole group) had a nonfatal reinfarction in 
the year after the initial arteriogram (Table 2). Of the 51 
eligible patients who did not have a repeat arteriogram at 1 
year, 4 had a nonfatal reinfarction (2 in each group). Thirteen 
patients who underwent a second arteriogram had a nonfatal 
reinfarction (seven in the aspirin and dipyridamole group, six 
in the placebo group). 
In the placebo group, two patients underwent angioplasty, 
and three had coronary artery bypass grafting, one of whom 
had a previous angioplasty. Four patients who received aspirin 
and dipyridamole had coronary artery bypass graft surgery, and 
two had angioplasty. Nine patients in the group with arteriog- 
raphy at 1 year underwent revascularization (five in the aspirin 
and dipyridamole group, four in the placebo group) compared 
with three in those without arteriography (two placebo). All 
interventions were for angina not adequately controlled by 
medical therapy. 
If a combined hierarchic ardiovascular end point (cardiac 
death, myocardial infarction or revascularization) was consid- 
ered, there was no significant difference in events in each 
group. Sixteen events (14.8%) occurred in patients receiving 
aspirin and dipyridamole, and 19 events (17.8%) occurred in 
patients receiving placebo. 
Infarct.related artery pateney. Patency findings at 4 weeks 
and 1 year are shown in Figure 1. Treatment with aspirin and 
dipyridamole did not significantly affect he overall reocclusion 
rates. At 1 year 38 patients (25%) had a reoccluded infarct- 
related artery (18 [23%] receiving aspirin and dipyridamole, 20 
[27%] receiving placebo, p = NS). If the 39 patients who did 
not receive thrombolytic therapy were excluded, the reocclu- 
sion rates were also similar (24% for 14 in the aspirin and 
dipyridamole group, 27% for 15 in the placebo group). 
Patients with more severe infarct-related artery stenoses 
were prone to reocclusion (p < 0.0l). The 1-year eocclusion 
rate was 9.2% for <50% stenosis (1 of 11 in the aspirin and 
dipyridamole group, 1 of 11 in the placebo group), 11.6% for 
50% to 69% stenosis (4 of 22 in the aspirin and dipyridamole 
group, 1 of 21 in the placebo group), 30.4% for 70% to 89% 
stenosis (10 of 42 in the aspirin and dipyridamole group, 14 of 
37 in the placebo group) and 70% for ->90% stenosis (3 of 4 in 
the aspirin and dipyridamole group, 4 of 6 in the placebo 
group). Figure 2 shows reocclusion rates for patients with 
->70% stenosis of the infarct-related artery for aspirin and 
dipyridamole (41.8%) versus placebo (28.3%), (p = 0.18). Six 
of the 154 patients who underwent coronary arteriography at1 
year had TIMI grade 2 flow in the infarct-related artery on the 
initial angiogram. Four (two in the placebo group) of these 
patients had an occluded infarct-related artery; one in the 
placebo group had TIMI grade 2 flow; and one in the aspirin 
and dipyridamole group had TIMI grade 3 flow. Potential risk 
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Figure 1. Reocclusion ofthe infarct-related artery at 1 year. Effect of 
treatment with aspirin and dipyridamole (hatched bar) compared with 
placebo (solid bar) (p = NS). Vertical bars = mean value + SD. 
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Figure 2. Reocclusion of the infarct-related artery related to treat- 
ment and stenosis severity. Reocclusion fthe infarct-related artery is 
grouped according topercent diameter stenosis on the index arterio- 
gram (<70% or >-70%). Patent arteries are represented byhatched 
bars and occluded arteries by solid bars. Patients with ->70% stenosis 
had more frequent reocclusion fthe infarct-related artery (34.8% vs. 
10.8%, p < 0.001). Of the six patients who had Thrombolysis in 
Myocardial Infarction trial (TIMI) grade 2 flow on the first arterio- 
gram, four had occlusions at1 year, one had TIMI grade 2 flow, and 
one had TIMI grade 3 flow. AD = aspirin and dipyridamole; P = 
placebo. 
factors for reocclusion are listed in Table 3. The majority of 
reocclusions were clinically silent, with only 17 patients (45% 
of reocclusions) having clinical reinfarction. The mean severity 
of the residual stenosis of the infarct-related coronary artery in 
patients with clinical reinfarction was similar to that in patients 
who had silent reinfarction (82% vs. 84%). 
Table 3. Potential Risk Factors for Reocclusion 
Pts With Pts With 
Patent Reoccluded 
Infarct-Related Infarct-Related 
Artery Artery 
(n = 116) (n : 38) 
P 
Value 
Age (yr) 55 + 8 57 ± 9 0.29 
Male gender 93 (80%) 29 (76%) 0.8 
Aspirin and dipyridamole 61 (53%) 18 (47%) 0.78 
Infarct-related artery 
RCA 56 (71%) 23 (29%) 
LAD 48 (81%) 11 (19%) 0.36* 
LCx 12 (75%) 4 (25%,) 
Continued smoking 17 (15%) 2 (5%) 0.22 
Diabetes 9 (8%) 1 (3%) 0.42 
Peak CK (IU/liter) 2,749 _+ 1,989 2,351 ± 1,671 0.18 
Hypertension 27 (23%) 15 (39%) 0.12 
Total cholesterol (mmol/liter)~" 6.6 _+ 1.3 6.6 + 0.9 0.97 
HDL cholesterol (mmol/liter)~ 1.1 + 0.29 1.08 ± 0.35 0.85 
*For three by two chi-square analysis. +Lipid concentrations measured at 
12-month follow-up. Data presented are mean value +_ SD or number (%) of 
patients (Pts). CK - creatine kinase; HDL - high density lipoprotein; LAD - 
left anterior descending coronary artery; LCx = left circumflex coronary artery; 
RCA = right coronary artery. 
Exercise testing 4 weeks after infarction did not differenti- 
ate between the likelihood of having an occluded or nonoc- 
eluded infarct-related artery at 1 year. Exercise duration was 
similar ([mean ~ SD] 11.3 _+ 3.3 vs. 11.8 _ 2.9 rain), and there 
was no difference in time to onset or amount of ischemic ST 
segment depression. 
There were no significant differences inpeak CK level after 
the initial infarction in patients with subsequent infarct-related 
artery patency (2,847 + 1,993 IU/liter vs. 2,351 + 1,671 IU/liter) 
and patients who did not develop reocdusion. 
Changes in left ventricular volume and ejection fraction 
between the 4-week and 1-year ventriculograms are shown in 
Table 4. There were no significant changes in ejection fraction 
during follow-up either with treatment assignment or patency 
of the infarct-related artery. End systolic volume rose by 8 mL 
(13%) with similar increases in patients allocated aspirin and 
dipyridamole and placebo. End systolic volume increased by a 
similar amount in patients with persisting infarct artery pa- 
tency and those in whom the infarct artery reoccluded. 
Discuss ion  
This study shows that late reocclusion of the infarct-related 
artery is frequent and occurs in 25% of patients between 4
weeks and 1 year after myocardial infarction. Frequent reoc- 
clusion occurred espite daily therapy with 50 mg of aspirin 
and 400 mg of dipyridamole. Reocclusion rates were higher in 
patients with more severe infarct-related artery stenoses, but 
these rates were not significantly altered by antiplatelet ther- 
apy. Although the primary end point of this study was to 
examine differences in 1-year patency, even if a combined 
hierarchic ardiovascular end point was considered, the com- 
bination of aspirin and dipyridamole had no significant effect. 
Reocclusion of the infarct-related artery was usually not 
associated with clinical reinfarction. The high percent of silent 
reocclusions may relate to the finding that these patients 
already had a partial infarct of the territory supplied by the 
infarct-related artery and to the development of collateral 
circulation. 
Previous studies. Earlier studies (22) have shown early 
reocclusion of infarct-related arteries in up to 20% of patients. 
In the Global Utilization of Streptokinase and t-PA for 
Occluded Arteries (GUSTO) trial (23), early reocclusion at 5 
to 7 days occurred in 4.9% to 6.4% of patients treated with 
aspirin and heparin plus either streptoldnase, accelerated 
rt-PA or combination therapy. Reinfarction occurred in 4% of 
patients (23). The Antithrombotics in the Prevention of Reoc- 
clusion in Coronary Thrombolysis (APRICOT) study [11] is 
the only previous tudy that has evaluated reocclusion rates 
beyond the first few weeks. That study determined the effects 
of aspirin (325 rag), coumadin (international normalized ratio 
2.8 to 4.8) or placebo n infarct-rdated artery patency between 
48 h and 3 months after thrombolytic and intravenous heparin 
therapy. There were no differences between the three treat- 
ments in terms of patency over this period. The total reocclu- 
sion rate between 48 h and 3 months was 29%. Patients who 
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Table 4. Changes in Left Ventricular Volume and Ejection Fraction Between 4 Weeks and 1 Year* 
Patent Occluded 
Aspirin and Dipyridamole Placebo Infarct-Related Infarct-Related 
Group Group Artery Artery 
(n = 77) (n = 73) (n = 112) (n = 38) 
End-systolic volume (ml) 
4 wk 59 _+ 33 64 ± 31 62 _+ 31 56 + 29 
1 yr 67 ± 42 71 ± 36 72 ± 42 63 ± 31 
Ejection fraction (%) 
4wk 59 ± 12 56_+ 12 57_+ 12 59 + 11 
1 yr 58 ± 15 56_+ 13 57 ± 15 57 ± 13 
*Four patients who had repeat coronary arteriography didnot have follow-up left ventriculography. Data presented 
are mean value ± SD. 
received aspirin were less likely to have a combined clinical 
end point of death, reinfarction or revascularization (7% vs. 
18% for coumadin, 24% for placebo). 
The ISIS-2 study (21) showed that 160 mg of aspirin given 
daily reduced death and recurrent myocardial infarction by 
50% at 35 days. Because side effects are related to the dose of 
aspirin (24), an important question is whether a lower dose is 
equally effective. The minimal effective regular daily dose of 
aspirin in patients with various clinical manifestations of 
coronary heart disease is unclear. Daily doses as low as 40 mg 
cause marked inhibition of both vascular and platelet cyclooxy- 
genase activity (25). A recent rial (26) examined the efficacy of 
50 mg of aspirin daily and 400 mg dipyridamole on saphenous 
vein graft occlusion and showed an incidence of 13% reocclu- 
sion at 1 year, which is similar to that reported in other studies 
(27) utilizing between 150 and 975 mg of aspirin daily. In 
patients with chronic stable (28) or unstable (29) angina, 75 mg 
of aspirin daily decreased the number of patients who had 
further myocardial infarction or unstable angina by -35%. 
Also, a Dutch study (30) showed that 30 and 300 mg of aspirin 
were similarly effective in the prevention of recurrent transient 
ischemic attacks. 
The other antiplatelet agent used in this study, dipyrida- 
mole, an inhibitor of phosphodiesterase, has not been clearly 
shown to be clinically efficacious except in conjunction with 
warfarin in the prevention of thrombus formation on pros- 
thetic heart valves (31). There is some evidence that dipyrid- 
amole may potentiate the in vitro and in vivo effects of low 
dose aspirin, such as 50 mg daily (26,31). However, important 
side effects may occur, leading to discontinuation of therapy 
(32). 
Mechanisms of reoeclusion and implications. The mecha- 
nisms of late reocclusion of the infarct-related artery have not 
been defined but may relate to both progression of atheroscle- 
rotic plaque and thrombosis. We did not identify any clinical 
risk factors for reocclusion. In this study reocclusion related 
partly to the degree of residual stenosis of the infarct-related 
artery. Of the six patients with TIMI grade 2 flow on the initial 
angiogram, four had a reoccluded infarct-related artery at 1 
year. There are few data available about the effects of various 
interventions, including angioplasty, on improving TIMI grade 
2 flow, which results in a worse outcome than TIMI grade 3 
flow (23). Our data do not show any significant changes in left 
ventricular volume in those patients whose infarct-related 
artery reoccluded in the year after myocardial infarction. 
However, our study was not statistically powered to address 
this issue. 
In the long-term follow-up period of the large mortality 
trials (21,33-35), there has been no clear evidence that the 
survival curves are diverging. This is somewhat unexpected 
given the improvement in left ventricular function with throm- 
bolytic therapy (36) and the long-term prognostic benefits of a 
patent infarct-related artery (8), which may relate to decreased 
ventricular arrhythmias (37), reduced ventricular remodeling 
(38) and provision of capacity for collateral blood flow to 
another infarct zone if further infarction occurs. The results of 
the current study may partly explain the lack of divergence, 
with a large number of infarct-related arteries reoccluding < 1 
year. It is not known how many arteries occlude after this time. 
Reduction in severity of the residual infarct-related artery 
stenosis by angioplasty, with lower shear forces, improvement 
of flow characteristics and consequent washing away of platelet 
aggregates, might be expected to reduce reocclusion rates. 
However, reocclusion rates at 6 months in patients undergoing 
angioplasty of a patent infarct-related artery within 24 h of 
thrombolytic therapy for myocardial infarction have been 
shown to be similar (25% to 35%) (39) to those of the present 
study at 1 year. In the primary angioplasty registry, reocclusion 
at 6 months was 13% (95% confidence interval 8% to 20%) 
(40). More information is required about the relative merits of 
angioplasty versus medical therapy for maintaining long-term 
patency. 
Conclusions. Late reocclusion of a patent infarct-related 
artery is a common event. Future strategies, including newer 
antiplatelet and antithrombotic regimens and their combina- 
tion, may play an important role in further improving the 
substantial benefits already shown by thrombolytic therapy. 
We thank the doctors and nurses who helped enroll and care for patients inthis 
study. 
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